Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing

The increased use of human papillomavirus testing within cervical screening programmes necessarily brings about changes to the laboratory services required to support them. A crucial element of such services is to demonstrate initial and ongoing quality of the test (and associated processes). In thi...

Full description

Saved in:
Bibliographic Details
Published in:Cytopathology (Oxford) 2019-05, Vol.30 (3), p.273-280
Main Authors: Cuschieri, Kate, Schuurman, Rob, Coughlan, Suzie
Format: Article
Language:English
Subjects:
Cervix Uteri - pathology
Cervix Uteri - virology
Early Detection of Cancer - standards
Female
Human papillomavirus
Humans
Laboratories
Mass Screening - standards
Medical screening
molecular testing
Papillomaviridae - pathogenicity
Papillomavirus Infections - diagnosis
Papillomavirus Infections - pathology
Papillomavirus Infections - virology
Quality
quality assurance
Quality Assurance, Health Care
Quality control
Uterine Cervical Neoplasms - diagnosis
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - virology
Vaginal Smears - standards
verification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increased use of human papillomavirus testing within cervical screening programmes necessarily brings about changes to the laboratory services required to support them. A crucial element of such services is to demonstrate initial and ongoing quality of the test (and associated processes). In this review, we outline some of the quality considerations and challenges with an emphasis on the laboratory including assay and platform validation, internal quality control selection and strengths and weaknesses of external quality assurance schemes. The influence and role of key external entities, including regulatory agencies, guideline groups, programme commissioners and commercial providers, are also discussed. Cervical screening will rely increasingly on high risk HPV testing. In this review the considerations and challenges for the laboratory around the introduction and assessment of appropriate quality‐monitoring, to support HPV based screening, will be described.
ISSN:0956-5507
1365-2303
DOI:10.1111/cyt.12679